Press Releases
Feb 20, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present fourth quarter and full-year 2019 financial results and
Feb 10, 2020
Summary ToggleIntellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Specific and potent tumor cell killing observed in WT1-positive acute myeloid leukemia blasts in vitro by TCR-based engineered T cells, supporting Intellia’s first engineered T cell therapy development candidate, NTLA-5001 Knockout of KLKB1 gene with CRISPR/Cas9 for hereditary angioedema results in
Jan 9, 2020
Summary ToggleIntellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020 Nominated NTLA-5001 for the treatment of acute myeloid leukemia as first WT1-TCR-directed engineered cell therapy development candidate; plan to submit IND
Nov 26, 2019
Summary ToggleIntellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference
CAMBRIDGE, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the Evercore ISI 2 nd Annual HealthCONx Conference on
Oct 31, 2019
Summary ToggleIntellia Therapeutics Announces Third Quarter 2019 Financial Results
On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy development candidate for the treatment of acute myeloid leukemia by the end of 2019
Oct 24, 2019
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2019 results and operational highlights in
Oct 24, 2019
Summary ToggleIntellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse model Inserted highly active WT1-TCR into the endogenous TCR locus for potential improved treatments for hematological and solid malignancies
Oct 16, 2019
Summary ToggleIntellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc . (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced one oral presentation and four poster
Sep 30, 2019
Summary ToggleIntellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conferences in
Sep 26, 2019
Summary ToggleArbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology
Interim Award concluded all technology in dispute was exclusively licensed to Intellia Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
